Comprehensive analysis of ZNF692 as a potential biomarker associated with immune infiltration in a pan cancer analysis and validation in hepatocellular carcinoma

Abstract

Currently, the roles of ZNF692 have been documented exclusively in lung, colon, and cervical cancers. However, its involvement in pan cancer remains unknown. In this study, we employed bioinformatics analysis and experimental validation to investigate the role of ZNF692 in pan cancer. Our findings revealed aberrant expression of ZNF692 across various types of cancer. High expression of ZNF692 was associated with poor overall survival (OS) in ACC, COAD, KIRC, LAML, and LIHC. ZNF692 exhibited promising diagnostic potential in certain tumor types. A significant correlation was observed between high ZNF692 expression and advanced stages of ACC, BLCA, KICH, KIRC, LIHC, and OV. The expression of ZNF692 exhibited a significant association with microsatellite instability (MSI) in eight types of cancer and tumor mutational burden (TMB) in ten types of cancer. A noteworthy correlation was observed between ZNF692 expression and immune infiltration as well as immune checkpoints. Amplification of ZNF692 emerged as the most frequent alteration in pan cancer. ZNF692 was implicated in various biological processes, cellular components, and molecular functions within the context of pan cancer. It is plausible that ZNF692 may contribute to chemotherapy and potentially be linked to chemoresistance. We constructed a competing endogenous RNA (ceRNA) network involving AC009403.11/miR-126-3p/ZNF692 in hepatocellular carcinoma (HCC). The expression of ZNF692 exhibited a notable upregulation in HCC cell lines. Aberrant expression of ZNF692 was observed across various types of cancer. ZNF692 holds potential as a valuable diagnostic, prognostic, and therapeutic target in the context of pan cancer.

ZNF692 promotes the migration and response to immunotherapy of clear cell renal cell carcinoma cells by targeting metabolic pathway

“…ZNF692 associates with the prognosis and proliferation of ccRCC [ 13 , 14 ]. In addition, ZNF692 may serve as a potential biomarker associated with immune infiltration in hepatocellular carcinoma [ 17 ]. However, the role of ZNF692 in ccRCC is largely unknown.…”

“…Recent reports have shown that ZNF692 is linked to the recurrence of Wilms’ tumor [ 12 ] , the prognosis and proliferation of ccRCC [ 13 , 14 ], and the aggressiveness of lung adenocarcinoma (LUAD) [ 15 ] and that it promotes the proliferation and invasion of cervical cancer cells [ 16 ]. In addition, ZNF692 may serve as a potential biomarker associated with immune infiltration in hepatocellular carcinoma [ 17 ]. Though, Wang et al reported that ZNF692 promoted the proliferation of ccRCC cells by targets IRF4 and FLT4 [ 14 ], however, the role of ZNF692 in ccRCC is largely unknown.…”